A Phase I/II Trial of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma.

Trial Profile

A Phase I/II Trial of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2013

At a glance

  • Drugs Obatoclax (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Feb 2013 New source identified and integrated (Mayo Clinic; 07-008520).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top